Affymetrix Q4 Revenues Inch up, Beat Analysts' Estimates on Top and Bottom Lines | GenomeWeb

NEW YORK (GenomeWeb) – Affymetrix said after the close of the market on Wednesday that total revenues moved up a fraction of 1 percent year over year in the fourth quarter.

For the three months ended Dec. 31, 2014 total revenues were $93.5 million compared to $92.6 million a year ago and above the consensus Wall Street estimate of $91.8 million. The revenues were slightly higher than those reported last month in Affymetrix's pre-announcement of revenues. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.